REG - Arecor Therapeutics - Posting of Circular and General Meeting

Arecor TherapeuticsAnnouncement

23/07/2024 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240723:nRSW5257Xa&default-theme=true

RNS Number : 5257X  Arecor Therapeutics PLC  23 July 2024

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, THE
REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH
RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT IS NOT AN OFFER FOR SALE OR SUBSCRIPTION IN ANY JURISDICTION
IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL UNDER THE
SECURITIES LAWS OF ANY SUCH JURISDICTION. THIS ANNOUNCEMENT IS NOT AN OFFER OF
OR SOLICITATION TO PURCHASE OR SUBSCRIBE FOR SECURITIES IN THE UNITED STATES.

 

23 July 2024

 

Arecor Therapeutics plc

 

("Arecor Therapeutics" or the "Company")

 

Posting of Circular and Notice of General Meeting

 

Arecor Therapeutics (AIM: AREC), the biopharmaceutical group advancing today's
therapies to enable healthier lives, is pleased to announce that further to
the announcement on 19 July 2024 confirming the results of the Placing and
Subscription, and the announcement earlier today confirming the results of the
Retail Offer, it is today posting to Shareholders the Circular including a
notice convening the General Meeting in respect of the conditional
Fundraising.

 

The General Meeting will be held at the offices of Covington & Burling LLP
at 22 Bishopsgate, London EC2N 4BQ at 1:00 p.m. on 8 August 2024.

 

The Circular will shortly be available on the Company's
website: www.arecor.com (http://www.arecor.com/)

 

Capitalised terms used in this announcement have the meanings given to them as
ascribed in the Company's announcement released at 1:10 p.m. on 19 July 2024.

 

For further information, please contact:

 

 Arecor Therapeutics plc                                                                www.arecor.com (http://www.arecor.com)

 Sarah Howell, Ph.D, Chief Executive Officer                                            Tel: +44 (0) 1223 426060

                                                                                        Email: info@arecor.com

 Panmure Liberum Limited (NOMAD, Joint Bookrunner and Joint Broker)                     Tel: +44 (0) 20 7886 2500

 Emma Earl, Freddy Crossley, Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint Bookrunner and Joint Broker)                                    Tel: +44 (0) 20 3705 9321

 Nigel Barnes, Satheesh Nadarajah

 David Wilson, Claes Spang

 Beech Hill Securities, Inc. (Placement Agent)                                          Tel: +1 212 350 7200

 George Billington, Thomas Lawrence

 ICR Consilium                                 Tel: +44 (0) 20 3709 5700

 Chris Gardner, David Daley, Lindsey Neville   Email: arecor@consilium-comms.com

Tel: +44 (0) 20 3705 9321

 

Beech Hill Securities, Inc. (Placement Agent)

George Billington, Thomas Lawrence

 

Tel: +1 212 350 7200

 

ICR Consilium

Chris Gardner, David Daley, Lindsey Neville

Tel: +44 (0) 20 3709 5700

Email: arecor@consilium-comms.com

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com/)

 

IMPORTANT NOTICES

This Announcement is not for publication or distribution, directly or
indirectly, in or into the United States of America.  This announcement is
not an offer of securities for sale into the United States.  The securities
referred to herein have not been and will not be registered under the
Securities Act, and may not be offered or sold in the United States, except
pursuant to an applicable exemption from registration.  No public offering of
securities is being made in the United States.

This Announcement does not constitute an offer to sell, or the solicitation of
an offer to acquire or subscribe for, Ordinary Shares in any jurisdiction
where such offer or solicitation is unlawful or would impose any unfulfilled
registration, qualification, publication or approval requirements on the
Company. The offer and sale of Ordinary Shares has not been and will not be
registered under the applicable securities laws of Australia, Canada, the
Republic of South Africa or Japan. Subject to certain exemptions, the Ordinary
Shares may not be offered to or sold within Australia, Canada, the Republic of
South Africa or Japan or to any national, resident or citizen of Australia,
Canada, the Republic of South Africa or Japan.

This Announcement does not constitute, or form part of, any offer or any
solicitation of an offer to subscribe for any shares or other securities, nor
shall it (or any part of it) or the fact of its dissemination form the basis
of, or be relied on in connection with, any contract with respect thereto.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CIRPPUWPMUPCGAW